Urogen Pharma Ltd. | Small-cap | Healthcare
$17.75
-4.52%
| Urogen Pharma Stock Comparison:
Urogen Pharma vs VertexUrogen Pharma vs RegeneronUrogen Pharma vs Harmony BiosciencesUrogen Pharma vs Ocular TherapeutixUrogen Pharma vs Beam TherapeuticsUrogen Pharma vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 20.3M
Gross Profit 17.9M 88.50%
Operating Income -36.9M -182.26%
Net Income -43.8M -216.47%
EPS (Diluted) $-0.92

Balance Sheet Metrics

Total Assets 247.6M
Total Liabilities 294.1M
Shareholders Equity -46.5M

Cash Flow Metrics

Operating Cash Flow -31.6M
Free Cash Flow -42.1M

Revenue & Profitability Trend

Urogen Pharma Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i90.4M82.7M64.4M48.0M11.8M
Cost of Goods Sold i8.9M9.4M7.7M5.2M1.0M
Gross Profit i81.5M73.4M56.7M42.9M10.8M
Gross Margin % i90.2%88.7%88.1%89.3%91.4%
Operating Expenses
Research & Development i57.1M45.6M52.9M47.6M47.3M
Selling, General & Administrative i121.2M93.3M82.8M87.5M90.2M
Other Operating Expenses i-----
Total Operating Expenses i178.3M138.9M135.7M135.2M137.5M
Operating Income i-96.8M-65.5M-79.0M-92.3M-126.7M
Operating Margin % i-107.1%-79.2%-122.8%-192.1%-1,074.2%
Non-Operating Items
Interest Income i8.9M2.6M938.0K365.0K2.0M
Interest Expense i12.5M14.7M8.4M0-
Other Non-Operating Income-23.6M-20.7M-21.5M-17.3M-
Pre-tax Income i-124.0M-98.3M-108.0M-109.4M-125.1M
Income Tax i2.8M3.9M1.8M1.4M3.4M
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-126.9M-102.2M-109.8M-110.8M-128.5M
Net Margin % i-140.4%-123.6%-170.6%-230.7%-1,088.9%
Key Metrics
EBITDA i-86.9M-60.4M-76.2M-90.3M-124.7M
EPS (Basic) i$-2.96$-3.55$-4.79$-4.96$-5.90
EPS (Diluted) i$-2.96$-3.55$-4.79$-4.96$-5.90
Basic Shares Outstanding i4287673728834303228068122234748121780826
Diluted Shares Outstanding i4287673728834303228068122234748121780826

Income Statement Trend

Urogen Pharma Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i172.0M95.0M55.4M44.4M52.9M
Short-term Investments i64.7M42.0M44.6M44.8M49.2M
Accounts Receivable i20.3M15.4M12.7M11.7M7.0M
Inventory i9.2M5.7M4.3M4.8M2.0M
Other Current Assets8.8M10.3M11.1M7.5M3.4M
Total Current Assets i276.1M169.2M128.9M114.4M115.6M
Non-Current Assets
Property, Plant & Equipment i4.3M2.8M3.5M2.1M2.7M
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets765.0K2.3M3.0M1.5M289.0K
Total Non-Current Assets i9.6M9.1M6.7M5.4M6.4M
Total Assets i285.7M178.3M135.6M119.7M122.0M
Liabilities
Current Liabilities
Accounts Payable i10.9M6.5M5.5M5.8M3.3M
Short-term Debt i-----
Current Portion of Long-term Debt-----
Other Current Liabilities7.9M3.9M3.3M3.3M1.9M
Total Current Liabilities i45.9M31.2M23.9M22.4M21.4M
Non-Current Liabilities
Long-term Debt i123.4M99.4M99.1M398.0K1.5M
Deferred Tax Liabilities i--3.0M2.8M2.7M
Other Non-Current Liabilities--98.9M85.7M2.7M
Total Non-Current Liabilities i248.6M212.3M201.1M89.0M4.2M
Total Liabilities i294.5M243.5M225.0M111.3M25.6M
Equity
Common Stock i115.0K89.0K63.0K61.0K60.0K
Retained Earnings i-806.2M-679.3M-577.1M-467.3M-356.5M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i-8.8M-65.2M-89.4M8.4M96.4M
Key Metrics
Total Debt i123.4M99.4M99.1M398.0K1.5M
Working Capital i230.2M138.0M105.0M92.0M94.2M

Balance Sheet Composition

Urogen Pharma Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-126.9M-102.2M-109.8M-110.8M-128.5M
Depreciation & Amortization i1.2M1.7M1.8M1.8M2.0M
Stock-Based Compensation i13.1M9.3M10.6M23.1M28.0M
Working Capital Changes i3.7M-41.0K-4.0M-7.6M-4.2M
Operating Cash Flow i-110.1M-90.2M-98.8M-94.7M-104.1M
Investing Activities
Capital Expenditures i-295.0K-194.0K-254.0K-752.0K-1.2M
Acquisitions i-----
Investment Purchases i-128.0M-49.8M-63.0M-51.9M-29.7M
Investment Sales i107.7M49.1M64.3M56.7M124.1M
Investing Cash Flow i-20.6M-953.0K1.1M4.1M93.2M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i24.5M095.8M0-
Debt Repayment i-----
Financing Cash Flow i175.7M67.4M95.6M72.3M15.8M
Free Cash Flow i-97.1M-76.6M-87.8M-85.6M-107.1M
Net Change in Cash i44.9M-23.8M-2.1M-18.3M4.9M

Cash Flow Trend

Urogen Pharma Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -6.55
Forward P/E -7.47
Price to Book -19.78
Price to Sales 10.00
PEG Ratio -7.47

Profitability Ratios

Profit Margin -150.68%
Operating Margin -182.26%
Return on Equity 1,441.26%
Return on Assets -29.80%

Financial Health

Current Ratio 5.65
Debt to Equity -2.72
Beta 1.13

Per Share Data

EPS (TTM) $-3.01
Book Value per Share $-1.01
Revenue per Share $2.02

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
urgn918.5M-6.55-19.781,441.26%-150.68%-2.72
Vertex 121.3B32.827.0522.77%31.86%8.89
Regeneron 60.4B14.371.9815.34%31.37%9.04
Harmony Biosciences 2.0B13.132.7424.71%20.50%24.63
Ocular Therapeutix 2.0B-7.40-57.19%91.17%28.66
Beam Therapeutics 1.9B-3.851.59-51.36%0.00%14.08

Financial data is updated regularly. All figures are in the company's reporting currency.